Virginia Suaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Virginia Suaya has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Agustin Cabillon
Ex residente del Servicio de Oncología Clínica, Hospital de Clínicas, Facultad de Medicina, Universidad de la República. Uruguay
1 shared publication - Cecilia Castillo
Prof. Agregada del Servicio de Oncología. Hospital de Clínicas “Dr. Manuel Quintela”. Facultad de Medicina. Universidad de la República. Montevideo, Uruguay
1 shared publication - Dahiana Amarillo
Asistente del Servicio de Oncología Clínica, Hospital de Clínicas, Facultad de Medicina, Universidad de la República. Uruguay
1 shared publication - Federico Garcia
Ex.Prof. Adjunto de la Clínica Médica C, Hospital de Clínicas, Facultad de Medicina, Universidad de la República. Uruguay
1 shared publication - Gabriel Krygier
Prof. Titular del Servicio de Oncología Clínica, Hospital de Clínicas, Facultad de Medicina, Universidad de la República. Uruguay
1 shared publication Natalia Camejo
Prof. Adjunta del Servicio de Oncología Clínica, Hospital de Clínicas, Facultad de Medicina, Universidad de la República. Uruguay
1 shared publication
Latest Publications
- Open Access
- 3 June 2026
- Published by AMO Publisher in European Journal of Medical and Health Research
- Vol. 4 (4) , 72-75
Overlap Syndrome of Myocarditis–Myositis– Myasthenia Induced by Immunotherapy in Advanced Melanoma: A Case Report
Immune checkpoint inhibitors have transformed the treatment of advanced melanoma; however, they may be associated with potentially severe immune-related adverse events. Among these, myocarditis–myositis– myasthenia overlap syndrome (MMM) is a rare but highly life-threatening condition. We report the case of an 84-year-old patient with stage IV melanoma treated with nivolumab and ipilimumab using a reduced-dose regimen, who initially developed immune-mediated hepatitis, followed by proximal muscle weakness, bulbar involvement, and myasthenic symptoms, associated with markedly elevated creatine kinase levels. During hospitalization, the patient developed complete atrioventricular block and significant troponin elevation, consistent with MMM overlap syndrome. Treatment with high-dose intravenous methylprednisolone followed by oral corticosteroids and pyridostigmine was initiated, resulting in favorable clinical evolution, with neurological improvement and hemodynamic stabilization without the need for second-line therapies. This case highlights the importance of early recognition of severe immune- related adverse events, the need for a multidisciplinary approach, and prompt initiation of immunosuppressive therapy, which may significantly improve clinical outcomes even in elderly patients.
- 3 June 2026
- Published by AMO Publisher in European Journal of Medical and Health Research
- Vol. 4 (4) , 72-75
Open AccessOverlap Syndrome of Myocarditis–Myositis– Myasthenia Induced by Immunotherapy in Advanced Melanoma: A Case Report
Immune checkpoint inhibitors have transformed the treatment of advanced melanoma; however, they may be associated with potentially severe immune-related adverse events. Among these, myocarditis–myositis– myasthenia overlap syndrome (MMM) is a rare but highly life-threatening condition. We report the case of an 84-year-old patient with stage IV melanoma treated with nivolumab and ipilimumab using a reduced-dose regimen, who initially developed immune-mediated hepatitis, followed by proximal muscle weakness, bulbar involvement, and myasthenic symptoms, associated with markedly elevated creatine kinase levels. During hospitalization, the patient developed complete atrioventricular block and significant troponin elevation, consistent with MMM overlap syndrome. Treatment with high-dose intravenous methylprednisolone followed by oral corticosteroids and pyridostigmine was initiated, resulting in favorable clinical evolution, with neurological improvement and hemodynamic stabilization without the need for second-line therapies. This case highlights the importance of early recognition of severe immune- related adverse events, the need for a multidisciplinary approach, and prompt initiation of immunosuppressive therapy, which may significantly improve clinical outcomes even in elderly patients.